The purpose of this study is to determine the safety and tolerability of the intranodal
administration of autologous monocyte-derived dendritic cells tolerised with Vitamin-D3 and
pulsed with myelin peptides (tolDC-VitD3) in multiple sclerosis patients . To select the most
appropriate regime for the development of future therapeutic trials.
To evaluate the preliminary proof of concept by clinical and/or radiological activity and